Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celsis In Vitro Technologies, a division of the global life sciences company Celsis International has reported the availability of Celsis InVitroCYP microsomes for preclinical research.
Subscribe to our email newsletter
The microsome product line formulated to deliver different classifications of cytochrome P450 (CYP) enzyme activity, high levels for inhibitions studies (InVitroCYP H-class), moderate levels for metabolic studies (InVitroCYP M-class) and custom activity levels (InVitroCYP C-class), Celsis InVitroCYP now enables researchers to choose a microsome product to optimize their specific study outcomes.
Philip Vorwald, vice president and general manager of Celsis In Vitro Technologies, said: “InVitroCYP is the first product for the ADME-Tox market that delivers microsome products specifically for metabolic or inhibition studies without compromising P450 values, and without the time and cost of custom blending.”